References
- 1. Levine GN, Bates ER, Bittl JA, et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: A report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines: An update of the 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention, 2011 ACCF/AHA guideline for coronary artery bypass graft surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease, 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction, 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes, and 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery. Circulation. 2016;134:e123-e155. doi: 10.1161/CIR.0000000000000404.10.1161/CIR.000000000000040427026020
- 2. Ibanez B, James S, Agewall S, et al. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation, the task force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). Eur Heart J. 2018;39:119-177. doi: 10.1093/eurheartj/ehx393.10.1093/eurheartj/ehx39328886621
- 3. Bhatt DL, Hulot JS, Moliterno DJ, Harrington RA. Antiplatelet and anticoagulation therapy for acute coronary syndromes. Circ Res. 2014;114:1929-1943. doi: 10.1161/CIRCRESAHA.114.302737.10.1161/CIRCRESAHA.114.30273724902976
- 4. Udell JA, Bonaca MP, Collet JP, et al. Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: A collaborative meta-analysis of randomized trials. Eur Heart J. 2016;37:390-399. doi: 10.1093/eurheartj/ehv443.10.1093/eurheartj/ehv44326324537
- 5. McClure MW, Berkowitz SD, Sparapani R, et al. Clinical significance of thrombocytopenia during a non-ST-elevation acute coronary syndrome. The platelet glycoprotein IIb/IIIa in unstable angina: Receptor suppression using integrilin therapy (PURSUIT) trial experience. Circulation. 1999;99:2892-2900. doi: 10.1161/01.cir.99.22.2892.10.1161/01.cir.99.22.289210359733
- 6. Cameron HA, Phillips R, Ibbotson RM, Carson PH. Platelet size in myocardial infarction. Br Med J (Clin Res Ed). 1983;287:449-451. doi: 10.1136/bmj.287.6390.449.10.1136/bmj.287.6390.44915487026411169
- 7. O'Malley T, Langhorne P, Elton RA, Stewart C. Platelet size in stroke patients. Stroke. 1995;26:995-999.10.1161/01.STR.26.6.9957762052
- 8. Asher E, Fefer P, Shechter M, et al. Increased mean platelet volume is associated with non-responsiveness to clopidogrel. Thromb Haemost. 2014;112:137-141. doi: 10.1160/TH13-10-0845.10.1160/TH13-10-084524696016
- 9. VanWijk Michiel, VanBavel Ed, Nieuwland R. Microparticles in cardiovascular diseases. Cardiovasc Res. 2003;59:277-287. doi: 10.1186/1471-2121-14-23.10.1186/1471-2121-14-23365141423607880
- 10. Jy W, Horstman LL, Arce M, Ahn YS. Clinical significance of platelet microparticles in autoimmune thrombocytopenias. J Lab Clin Med. 1992;119:334-345.
- 11. Ozner MD, Ahn YS, Horstman LL, Jy W, Kolodny L, Myerberg RJ. Chronic platelet activation and acute coronary syndromes in 13 middle-aged patients. Clin Appl Thromb Hemost. 1997;3:46-53.10.1177/107602969700300107
- 12. Jachmann-Jahn U, Cornely OA, Laufs U, et al. Acute anterior myocardial infarction as first manifestation of acute myeloid leukemia. Ann Hematol. 2001;80:677-681.10.1007/s00277010035311757728
- 13. Shah AH, Anderson RA, Khan AR, Kinnaird TD. Management of immune thrombocytic purpura and acute coronary syndrome: A double-edged sword! Hellenic J Cardiol. 2016;pii:S1109-9666(16)30151-8. doi: 10.1016/j.hjc.2014.10.001.10.1016/j.hjc.2014.10.00127639318
- 14. Kohl BA. Con: Should aspirin be continued after cardiac surgery in the setting of thrombocytopenia? J Cardiothorac Vasc Anesth. 2006;20:114-116. doi: 10.1053/j.jvca.2005.10.007.10.1053/j.jvca.2005.10.00716458230
- 15. McCarthy CP, Steg G, Bhatt DL. The management of antiplatelet therapy in acute coronary syndrome patients with thrombocytopenia: a clinical conundrum. Eur Heart J. 2017;38:3488-3492. doi: 10.1093/eurheartj/ehx531.10.1093/eurheartj/ehx531583766129020292
- 16. Wang TY, Ou FS, Roe MT, et al. Incidence and prognostic significance of thrombocytopenia developed during acute coronary syndrome in contemporary clinical practice. Circulation. 2009;119:2454-2462. doi: 10.1161/CIRCULATIONAHA.108.827162.10.1161/CIRCULATIONAHA.108.82716219398666
- 17. Yadav M, Généreux P, Giustino G, et al. Effect of baseline thrombocytopenia on ischemic outcomes in patients with acute coronary syndromes who undergo percutaneous coronary intervention. Can J Cardiol. 2016;32:226-233. doi: 10.1016/j.cjca.2015.05.020.10.1016/j.cjca.2015.05.02026341303
- 18. McClure MW, Berkowitz SD, Sparapani R, et al. Clinical significance of thrombocytopenia during a non-ST-elevation acute coronary syndrome. The platelet glycoprotein IIb/IIIa in unstable angina: Receptor suppression using integrilin therapy (PURSUIT) trial experience. Circulation. 1999;99:2892-2900. doi: 10.1161/01.cir.99.22.2892.10.1161/01.cir.99.22.289210359733
- 19. Warkentin TE, Crowther MA. Adverse prognostic significance of thrombocytopenia in acute coronary syndrome. Can anything be done about it? Circulation. 2009;119:2420-2422. doi: 10.1161/CIRCULATIONAHA.109.858316.10.1161/CIRCULATIONAHA.109.85831619433766
- 20. Yusuf SW, Iliescu C, Bathina JD, Daher IN, Durand JB. Antiplatelet Therapy and Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome and Thrombocytopenia. Tex Heart Inst J. 2010;37:336-340.
- 21. Schwartz RS. Immune thrombocytopenic purpura – from agony to agonist. N Engl J Med. 2007;357:2299-2301. doi: 10.1056/NEJMe0707126.10.1056/NEJMe070712618046034